Methemoglobinemia is a blood condition in which hemoglobin, the protein in red blood cells that carries oxygen, becomes chemically altered so it can no longer deliver oxygen to your tissues effectively. In healthy people, less than 2% of hemoglobin exists in this altered “methemoglobin” form. When that percentage climbs above 10% to 20%, symptoms begin to appear, and levels above 70% can be fatal.
The condition can be triggered by certain medications, chemical exposures, or inherited enzyme deficiencies. It’s sometimes called “blue baby syndrome” when it affects infants exposed to nitrates in contaminated water.
How Methemoglobin Differs From Normal Hemoglobin
Normal hemoglobin contains iron in a form (ferrous iron) that readily picks up oxygen in the lungs and releases it throughout the body. In methemoglobinemia, that iron gets oxidized into a different form (ferric iron) that cannot bind oxygen. Your red blood cells are still circulating, but a growing fraction of them are essentially carrying empty seats.
Making matters worse, the remaining normal hemoglobin holds onto its oxygen more tightly when methemoglobin is present. So not only is less oxygen being picked up, less is being dropped off where it’s needed. This double effect is why even moderate levels of methemoglobin can cause significant oxygen deprivation in tissues.
Your body normally keeps methemoglobin in check with an enzyme called cytochrome b5 reductase, which continuously converts the altered iron back to its functional form. Problems arise when this enzyme is overwhelmed by a chemical exposure or is genetically deficient from birth.
Symptoms at Different Levels
The severity of methemoglobinemia tracks closely with the percentage of hemoglobin that has been converted. At low levels, you may notice nothing at all. As the percentage rises, symptoms progress in a fairly predictable pattern:
- Below 10%: Usually no symptoms. Skin may appear slightly pale, gray, or bluish. A pulse oximeter may give an unusually low reading.
- 10% to 30%: Visible cyanosis, a bluish discoloration of the skin and lips. Blood drawn at this stage looks dark brown rather than the usual deep red. Many people still feel relatively fine, though some experience confusion.
- 30% to 50%: Shortness of breath, dizziness, fainting, headache, chest pain, palpitations, and fatigue. These symptoms reflect your tissues genuinely starving for oxygen.
- 50% to 70%: Rapid breathing, abnormal heart rhythms, seizures, delirium, and coma. Metabolic acidosis develops as cells shift to less efficient energy production.
- Above 70%: Severe oxygen deprivation and a high risk of death.
One hallmark clue is chocolate-brown colored blood. If a blood sample is placed on white filter paper and exposed to oxygen, normal blood turns bright red. Methemoglobin-rich blood stays brown.
Common Causes in Adults
Most cases of methemoglobinemia are acquired, meaning they’re triggered by an outside substance rather than a genetic condition. Two medications alone account for roughly 45% of all drug-induced cases: dapsone (an antibiotic used for certain skin conditions and infections) and benzocaine (a topical anesthetic found in many over-the-counter throat sprays and oral pain products).
Other well-known triggers include sulfonamide antibiotics, the antimalarial drugs primaquine and chloroquine, certain seizure medications, nitrate-based heart medications, and phenazopyridine (a urinary pain reliever that turns urine orange). Nitrite compounds used in food preservation and industrial chemicals can also cause it.
The risk tends to be dose-dependent. A single standard application of a benzocaine throat spray rarely causes trouble, but repeated or excessive use, especially on broken skin or mucous membranes, can push methemoglobin levels into dangerous territory quickly.
Why Infants Are Especially Vulnerable
Babies under six months face a unique risk from nitrate-contaminated well water. Infants have relatively low stomach acidity compared to adults, which allows certain bacteria to thrive in their digestive tract. These bacteria efficiently convert nitrates (common in agricultural runoff and some well water) into nitrites, which then enter the bloodstream and oxidize hemoglobin.
This is the origin of the term “blue baby syndrome.” Infants who develop methemoglobinemia from nitrate exposure turn visibly blue or gray. The risk is highest in rural areas where families rely on private wells that may not be regularly tested for nitrate levels.
Benzocaine products pose an additional hazard for young children. In 2018, the FDA issued a safety warning that over-the-counter oral benzocaine products should not be used on infants and children younger than 2 years. The agency specifically warned against using benzocaine gels for teething pain, stating that the risks of methemoglobinemia far outweigh any potential benefits. Manufacturers were urged to stop marketing these products for teething altogether and to add methemoglobinemia warnings to labels for products intended for older children and adults.
The Inherited Forms
Congenital methemoglobinemia is caused by mutations in the CYB5R3 gene, which provides the blueprint for cytochrome b5 reductase, the enzyme responsible for keeping methemoglobin levels low. There are two types, and they differ dramatically in severity.
Type I affects only red blood cells. The enzyme still works but at reduced capacity, leading to methemoglobin levels between 10% and 50%. People with Type I typically have bluish skin from birth and may experience mild fatigue, but they often live normal lives. Other cells in the body can compensate for the reduced enzyme activity, so the condition remains limited to the blood.
Type II involves a complete loss of enzyme function throughout the body. Methemoglobin levels can reach 10% to 70%, and because the enzyme is missing from all cell types, not just red blood cells, the condition causes severe neurological problems including developmental delays. Type II is far rarer and far more serious.
Both forms are autosomal recessive, meaning a child must inherit a defective copy of the gene from each parent to develop the condition.
Why Pulse Oximeters Give Misleading Readings
One of the trickiest aspects of methemoglobinemia is that standard monitoring tools can be unreliable. A pulse oximeter, the clip placed on your finger, works by shining two wavelengths of light through your skin and measuring how much is absorbed. It’s designed to distinguish between hemoglobin carrying oxygen and hemoglobin without it. Methemoglobin absorbs light differently from either, which confuses the device.
In practice, pulse oximeters in methemoglobinemia patients tend to plateau around 82% to 85%, regardless of how high the actual methemoglobin level is. Meanwhile, a standard blood gas calculation may report a falsely normal oxygen saturation because it assumes all hemoglobin is in one of two normal states. The gap between these two readings, called the “saturation gap,” is a clinical red flag. A gap greater than 5% suggests an abnormal form of hemoglobin may be present.
Definitive diagnosis requires a specific blood test called co-oximetry, which can directly measure the percentage of methemoglobin in a blood sample.
How Methemoglobinemia Is Treated
For mild cases caused by a medication or chemical exposure, simply removing the trigger and providing supplemental oxygen may be enough. The body’s own enzyme system will gradually convert methemoglobin back to functional hemoglobin over several hours.
When methemoglobin levels climb above 20% to 30%, or when a patient is symptomatic at lower levels, the standard treatment is an intravenous dye called methylene blue. This works by providing an alternative chemical pathway for converting ferric iron back to its oxygen-carrying ferrous form. Most patients see rapid improvement, with methemoglobin levels dropping within minutes of treatment.
There is one important exception. People with a condition called G6PD deficiency, an inherited enzyme shortage that affects roughly 400 million people worldwide, cannot safely receive methylene blue. The treatment depends on a chemical pathway that requires G6PD to function, and giving it to a deficient patient can trigger a dangerous breakdown of red blood cells. For these individuals, treatment relies on vitamin C (ascorbic acid) and supportive oxygen therapy instead. Because G6PD deficiency is common in populations of African, Mediterranean, and Southeast Asian descent, screening for it matters when methemoglobinemia treatment is being considered.
For people with the inherited form, chronic low-dose vitamin C or methylene blue taken by mouth can help keep methemoglobin levels manageable, though Type II remains difficult to treat because of its neurological effects.